Příspěvky

Zobrazují se příspěvky z září, 2012

Diagnosis and Treatment of Basal Cell Carcinoma

Hereditární nádorové syndromy

Akreditovaná pracoviště » Moje Medicina

Neuroendocrine Tumors: Update on Somatostatin Analogues

Obrázek
111In-pentetreotide scintigraphy of the 41 year-old man with ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery. Radiotracer accumulation in the left thyroid in 10/2003 (arrow). The mesenterial neuroendocrine tumor became clearly visible in 4/2005 (arrow). (Photo credit: Wikipedia) Neuroendocrine Tumors: Update on Somatostatin Analogues
Related articlesResearchers test new drug for patients with neuroendocrine tumorsTesting Of New Drug For Patients With Neuroendocrine TumorsMoffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumorsDrug ideal for p-NET therapy: Pfizer

Neuroendocrine Tumors: Update on Molecularly Targeted Therapies

Obrázek

PICC and associated symptomatic upper extremity venous thrombosis

Persistent hiccup caused by PICC migration

Incidence of migration of central line tips from the SVC to the azygous vein

Obrázek

Risk factors: PICC related related large vein thrombosis

Obrázek

PICC and associated symptomatic upper extremity venous thrombosis

Obrázek

Research study: Valved versus open PICC occlusion rates

Obrázek

Power injectable peripherally inserted central venous catheters (PICC) flip after power injection

Obrázek

Reducing PICC diameter to a maximum of 5Fr is associated with a significant decrease in the rate of PICC-associated DVT

Obrázek

PICC

Obrázek
A typical peripherally inserted central catheter. The maker's logo has been intentionally painted out. This is a single lumen model, but they are also available in two and three lumen models. (Photo credit: Wikipedia)TYPY KATETRŮ



ARROWGROSHONG- singl či multi lumen





PÉČE

zásady: asepticky, stříkačky 10 ml

návrat krve 4-5 ml

proplach: F1/1 10 ml ( před a po aplikaci léku )

F1/1 20 ml po odběru krve

při proplachu používat techniku 'push-pause' - po každém ml roztoku udělat pauzu - vznikající turbulence umožní snadnější proplach a zabraňuje ucpávání katetrusnaha zachování pozitivního tlaku na konci katetru - při posledním aplikovaném ml zasvorkovat

zátka: HEPARINOVÁ ZÁTKA pouze pro ARROW PICC

- při opakovaném používání v průběhu dne - jen F1/1 10ml

- při používání po více jak 1 dni - heprinová zátka 5 ml s HEPARINEM 10j/ml ( delší nepoužívání katetru udává 100j/ml )



Frekvence výkonů:

- převaz krytí po zavedení za 1-3 dny - při používání 1x za 7 dnů (transparentní krytí)





Fixace katetru…

AngioDynamics earns FDA clearance for BioFlo technology vascular access device to reduce catheter-related thrombus

Incidence, diagnosis, prevention and treatment of PICC related upper extremity DVT

Obrázek

The FDA have recently warned about the cardiac effect of a 32 mg single intravenous (IV) dose of ondansetron

Obrázek
Intravenous Therapy News and Updates with IVTEAM » The FDA have recently warned about the cardiac effect of a 32 mg single intravenous (IV) dose of ondansetron

Doporučení k aplikaci ondansetronu:

max. 0,15 mg\/kg každé 4 hodiny max tři dávky; však žádná jednotlivá intravenózní dávka nesmí překročit 16 mg.

Comparison of catheter-related large vein thrombosis in centrally inserted versus peripherally inserted central catheters

Obrázek
Intravenous Therapy News and Updates with IVTEAM » Comparison of catheter-related large vein thrombosis in centrally inserted versus peripherally inserted central catheters

CONCLUSIONS: In neurological critical care patients, CICVCs appear to have a better risk profile compared to PICCs, with a decreased risk of CRLVT. As use of PICCs in critical care patients increases, a prospective randomized trial comparing PICCs and CICVCs in neurological critical care patients is necessary to assist in choosing the appropriate catheter and to minimize risks of morbidity and mortality associated with central venous access.

PICC Lines od Erin Powell na Prezi

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial | DocGuide

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial | DocGuide

Subcutaneous trastuzumab, administered over about 5 min, has a pharmacokinetic profile and efficacy non-inferior to standard intravenous administration, with a similar safety profile to intravenous trastuzumab, and therefore offers a valid treatment alternative.

The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes | DocGuide

Obrázek